Pazopanib versus sunitinib in Chinese patients with locally advanced or metastatic renal cell carcinoma: pooled subgroup analysis from the randomized, COMPARZ studies | BMC Cancer | Full Text

Pazopanib versus sunitinib in Chinese patients with locally advanced or metastatic renal cell carcinoma: pooled subgroup analysis from the randomized, COMPARZ studies | BMC Cancer | Full Text

Pazopanib versus sunitinib in Chinese patients with locally advanced or metastatic renal cell carcinoma: pooled subgroup analysis from the randomized, COMPARZ studies

We performed a pooled analysis of the COMPARZ study assessing efficacy and safety of pazopanib versus sunitinib in treatment-naïve Chinese patients with locally advanced and/or metastatic renal cell carcinoma ...

Authors:Xinan Sheng, Jie Jin, Zhisong He, Yiran Huang, Aiping Zhou, Jinwan Wang, Xiubao Ren, Dingwei Ye, Xu Zhang, Shukui Qin, Fangjian Zhou, Binhui Wang and Jun Guo

Citation:BMC Cancer 2020 20:219

Content type:Research article

Published on: 14 March 2020

• ViewFull Text
 
• ViewPDF